NKG2A-checkpoint inhibition and its blockade critically depends on peptides presented by its ligand HLA-E
{{output}}
NKG2A has emerged as a new immunotherapy target and its blockade with the novel immune checkpoint inhibitor (ICI) monalizumab can boost both NK cell and CD8+ T cell responses. NKG2A forms heterodimers with CD94 and binds to the human non-classical MHC class I ... ...
